MissionIRNewsBreaks – NanoViricides (NYSE American: NNVC) Reports Fiscal 2026 Results, Advances NV-387 Phase II Trials

NanoViricides, Inc. (NYSE American: NNVC) reported results for its fiscal year ended June 30, 2026, highlighting regulatory and clinical progress for broad-spectrum antiviral candidate NV-387. The company received regulatory approval in the Democratic Republic of Congo for Phase II trials evaluating NV-387 Oral Gummies for the treatment of Mpox and Ebola, with both trials beginning […]